Hepatitis B reactivation related to everolimus

World Journal of Hepatology

Volumn 5, Issue 1, 2013, Pages 43-45

  Göksu, Sema Sezgin ^a   Bilal, Şerife ^a   Coşkun, Hasan şenol ^a  

^a AKDENIZ UNIVERSITY   (Turkey)

Author keywords

Everolimus; Hepatitis B; Immunosuppressive treatment; Mammalian target of rapamycin inhibitors; Renal cell carcinoma; Virus reactivation

Indexed keywords

EID: 84879143794     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v5.i1.43     Document Type: Article

References (14)

1. Oketani M, Ido A, Uto H, Tsubouchi H. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 2012; 42: 627-636 [PMID: 22686858 DOI: 10.1111/j.1872- 034X.2012.00998.x]
2. EU SmPC Afinitor. Available from: URL: http: //www. Ema.europa.eu/humandocs/Humans/EPAR/afinitor/ afinitor.htm. Accessed November 8, 2010
3. Manzano-Alonso ML, Castellano-Tortajada G. Reactivation of hepatitis B virus infection after cytotoxic chemotherapy or immunosuppressive therapy. World J Gastroenterol 2011; 17: 1531-1537 [PMID: 21472116 DOI: 10.3748/wjg.v17.i12.1531]
4. Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, Bracarda S, Grünwald V, Thompson JA, Figlin RA, Hollaender N, Kay A, Ravaud A. Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 2010; 116: 4256-4265 [PMID: 20549832 DOI: 10.1002/cncr.25219]
5. Casanovas T, Argudo A, Peña-Cala MC. Everolimus in clinical practice in long-term liver transplantation: an observational study. Transplant Proc 2011; 43: 2216-2219 [PMID: 21839237 DOI: 10.1016/j.transproceed.2011.06.015]
6. Kawahara T, Asthana S, Kneteman NM. m-TOR inhibitors: what role in liver transplantation? J Hepatol 2011; 55: 1441-1451 [PMID: 21781947 DOI: 10.1016/j.jhep.2011.06.015]
7. Torres HA, Davila M. Reactivation of hepatitis B virus and hepatitis C virus in patients with cancer. Nat Rev Clin Oncol 2012; 9: 156-166 [PMID: 22271089 DOI: 10.1038/nrclinonc. 2012.1]
8. Ohno M, Narita Y, Miyakita Y, Ueno H, Kayama T, Shibui S. Reactivation of hepatitis B virus after glioblastoma treatment with temozolomide--case report. Neurol Med Chir (Tokyo) 2011; 51: 728-731 [PMID: 22027252 DOI: 10.2176/nmc.51.728]
9. Cheong K, Li J, Karapetis CS. Gemcitabine and reactivation of hepatitis B. Med Oncol 2003; 20: 385-388 [PMID: 14716036 DOI: 10.1385/MO: 20: 4: 385]
10. Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY. Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 2011; 22: 1170-1180 [PMID: 21115603 DOI: 10.1093/annonc/mdq583]
11. Kang BW, Lee SJ, Moon JH, Kim SN, Chae YS, Kim JG, Hwang YJ, Sohn SK. Chronic myeloid leukemia patient manifesting fatal hepatitis B virus reactivation during treatment with imatinib rescued by liver transplantation: case report and literature review. Int J Hematol 2009; 90: 383-387 [PMID: 19641858]
12. Mastroianni CM, Lichtner M, Citton R, Del Borgo C, Rago A, Martini H, Cimino G, Vullo V. Current trends in management of hepatitis B virus reactivation in the biologic therapy era. World J Gastroenterol 2011; 17: 3881-3887 [PMID: 22025876]
13. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, Chan AT, Mok TS, Lee JJ, Leung TW, Zhong S, Johnson PJ. Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 2004; 22: 927-934 [PMID: 14990649 DOI: 10.1200/JCO.2004.05.161]
14. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, Csako G. Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 2008; 148: 519-528 [PMID: 18378948]